Hypertension and obesity moderate the relationship between β‐amyloid and cognitive decline in midlife
- 24 October 2018
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 15 (3) , 418-428
Abstract
Background: This study tested if central obesity, hypertension, or depressive symptoms moderated the relationship between β‐amyloid (Aβ) and longitudinal cognitive performance in late middle‐aged adults enriched for Alzheimer's disease (AD) risk.Methods: Participants (n = 207; ages = 40–70 years; 73% parental AD) in the Wisconsin Registry for Alzheimer's Prevention study completed 3+ neuropsychological evaluations and a [11C]PiB positron emission tomography scan or lumbar puncture. Linear mixed‐effects regression models tested interactions of risk factor × Aβ × visit age on longitudinal Verbal Learning & Memory and Speed & Flexibility factor scores.Results: The relationship between Aβ and Verbal Learning & Memory decline was moderated by hypertension (χ2(1) = 3.85, P = .04) and obesity (χ2(1) = 6.12, P = .01); those with both elevated Aβ and the risk factor declined at faster rates than those with only elevated Aβ or elevated risk factors.Conclusion: In this cohort, hypertension and obesity moderated the relationship between Aβ and cognitive decline.Keywords
Funding Information
- National Institutes of Health (R01 AG021155 (S.C.J.), R01 AG027161 (S.C.J.), ADRC P50 AG033514 (S.A.), R01AG037639 (B.B.B.), R01 AG054059, F30 AG054115 (S.E.B.), T32 GM007507 (S.E.B.), T32 GM008692 (S.E.B.), T32 CA009206 (T.J.B.))
This publication has 65 references indexed in Scilit:
- Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age personsNeurobiology of Aging, 2012
- New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsBritish Journal of Clinical Pharmacology, 2012
- The projected effect of risk factor reduction on Alzheimer's disease prevalenceThe Lancet Neurology, 2011
- Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease.Neuropsychology, 2010
- Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related DisordersBiological Psychiatry, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer DiseaseArchives of Neurology, 2009
- Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseBrain, 2008
- Cerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older womenJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Depression and Risk for Alzheimer DiseaseArchives of General Psychiatry, 2006